Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -258,013.33%.

  • Lyell Immunopharma's EBITDA Margin fell 13028980.00% to -258,013.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -795,656.10%, marking a year-over-year decrease of 47494499.00%. This contributed to the annual value of -561,654.10% for FY2024, which is 38694102.00% down from last year.
  • Per Lyell Immunopharma's latest filing, its EBITDA Margin stood at -258,013.33% for Q3 2025, which was up 51.76% from -534,812.50% recorded in Q2 2025.
  • Lyell Immunopharma's EBITDA Margin's 5-year high stood at -12.40% during Q4 2022, with a 5-year trough of -2,396,633.33% in Q3 2022.
  • Its 3-year average for EBITDA Margin is -611,626.04%, with a median of -352,323.08% in 2024.
  • In the last 5 years, Lyell Immunopharma's EBITDA Margin plummeted by 239,485,428bps in 2022 and then skyrocketed by 219,801,333bps in 2023.
  • Lyell Immunopharma's EBITDA Margin (Quarterly) stood at -3,021.40% in 2021, then skyrocketed by 300,900bps to -12.40% in 2022, then tumbled by 39,877,991bps to -398,792.31% in 2023, then slumped by 135,033,497bps to -1,749,127.27% in 2024, then crashed by 13,028,980bps to -258,013.33% in 2025.
  • Its last three reported values are -258,013.33% in Q3 2025, -534,812.50% for Q2 2025, and -747,542.86% during Q1 2025.